S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
The only accurate crypto trading system I know … (Ad)
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
He Is Giving Away Bitcoin (Ad)
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
Biden’s $374B Giveaway Into This Sector (Ad)
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
The only accurate crypto trading system I know … (Ad)
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
He Is Giving Away Bitcoin (Ad)
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
Biden’s $374B Giveaway Into This Sector (Ad)
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
The only accurate crypto trading system I know … (Ad)
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
He Is Giving Away Bitcoin (Ad)
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
Biden’s $374B Giveaway Into This Sector (Ad)
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
The only accurate crypto trading system I know … (Ad)
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
He Is Giving Away Bitcoin (Ad)
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
Biden’s $374B Giveaway Into This Sector (Ad)
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
Free Trial
NYSE:ARA

American Renal Associates (ARA) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)
Free ARA Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$11.33
▼
$11.52
50-Day Range
$11.46
▼
$11.52
52-Week Range
$5.57
▼
$11.98
Volume
9,831 shs
Average Volume
106,940 shs
Market Capitalization
$397.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
ARA stock logo

About American Renal Associates Stock (NYSE:ARA)

American Renal Associates Holdings, Inc. operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease. As of December 31, 2019, it operated 246 dialysis clinics in partnership with 400 nephrologist partners treating approximately 17,300 patients in 27 states and the District of Columbia. The company was founded in 1999 and is headquartered in Beverly, Massachusetts.

ARA Stock News Headlines

August 31, 2023 | benzinga.com
Bayer's Kerendia® (finerenone) Included in Latest Focused Guideline Clinical Updates from European Society of Cardiology
February 22, 2023 | finance.yahoo.com
Anemia in Chronic Kidney Disease (Renal Anemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
April 18, 2024 | DTI (Ad)
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
January 11, 2023 | finance.yahoo.com
Liberation From Renal Replacement Therapy and Early Initiation to Be Supported by The Kidney Function Biomarker Proenkephalin A 119-159 (penKid)
January 2, 2023 | finance.yahoo.com
Continuous Renal Replacement Therapy Global Market Report 2022: Rising Prevalence of Acute Kidney Injuries Drives Demand
October 7, 2022 | bbc.com
Dalian Atkinson: Footballer killed hours before renal treatment
June 22, 2022 | finance.yahoo.com
ARA Appoints James Myers Vice President, Program Innovation and Growth
June 20, 2022 | thestreet.com
American Renal Associates Holdings, Inc. News
April 18, 2024 | DTI (Ad)
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
December 6, 2021 | markets.businessinsider.com
SEC Charges Dialysis Provider and Three Former Senior Executives with Revenue Manipulation Scheme
December 6, 2021 | law360.com
SEC Hits Dialysis Co., Execs With Accounting Fraud Claim
December 6, 2021 | nasdaq.com
U.S. SEC charges dialysis provider, three former executives with revenue manipulation
October 21, 2021 | sg.finance.yahoo.com
Strive Health Unveils Strive Care Partners, Reaches 500 Nephrology Partners
October 19, 2021 | investing.com
American Renal Associates Holdings Inc (ARA)
See More Headlines
Receive ARA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for American Renal Associates and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/11/2020
Today
4/18/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Miscellaneous Health & Allied Services
Sub-Industry
N/A
Current Symbol
NYSE:ARA
CUSIP
N/A
CIK
1498068
Web
www.americanrenal.com
Phone
978-922-3080
Fax
N/A
Employees
4,977
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
$0.26
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-13,790,000.00
Net Margins
-2.04%
Pretax Margin
N/A
Return on Equity
-3.56%
Return on Assets
-0.24%

Debt

Debt-to-Equity Ratio
7.54
Current Ratio
1.05
Quick Ratio
1.02

Sales & Book Value

Annual Sales
$822.52 million
Price / Sales
0.48
Cash Flow
$1.69 per share
Price / Cash Flow
6.80
Book Value
$2.59 per share
Price / Book
4.45

Miscellaneous

Outstanding Shares
34,543,000
Free Float
N/A
Market Cap
$397.94 million
Optionable
Optionable
Beta
1.11
7 Stocks to Buy And Hold Forever Cover
7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Mr. Joseph A. Carlucci (Age 66)
    Co-Founder, CEO & Chairman
    Comp: $1.06M
  • Mr. Syed T. Kamal (Age 67)
    Co-Founder, Pres & Director
    Comp: $947.14k
  • Dr. Don E. Williamson (Age 58)
    Exec. VP & COO
    Comp: $1.22M
  • Mr. Mark C. Herbers (Age 65)
    Interim CFO & Interim Chief Accounting Officer
  • Mr. Richard Pacheco CFE
    AVA, MBA, VP of Admin.
  • Mr. Neal Minahan
    Chief Compliance Officer & VP
  • Ms. Victoria A. Labriola Esq.
    M.B.A., VP, Gen. Counsel & Sec.
  • Ms. Jennifer Hood
    VP of HR
  • Dr. Richard Cronin M.D.
    Chief Medical Officer
  • Ms. Shari Cousins R.N.
    C.N.N., Sr. VP of Clinical & Regulatory Services

Key Competitors

View All Competitors

ARA Stock Analysis - Frequently Asked Questions

How were American Renal Associates' earnings last quarter?

American Renal Associates Holdings, Inc. (NYSE:ARA) issued its quarterly earnings results on Wednesday, November, 11th. The company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.09. The firm had revenue of $209.69 million for the quarter, compared to analysts' expectations of $211.50 million. American Renal Associates had a negative trailing twelve-month return on equity of 3.56% and a negative net margin of 2.04%.

What is Joseph Carlucci's approval rating as American Renal Associates' CEO?

62 employees have rated American Renal Associates Chief Executive Officer Joseph Carlucci on Glassdoor.com. Joseph Carlucci has an approval rating of 57% among the company's employees. This puts Joseph Carlucci in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of American Renal Associates own?

Based on aggregate information from My MarketBeat watchlists, some companies that other American Renal Associates investors own include Zevra Therapeutics (KMPH), Exelixis (EXEL), Amicus Therapeutics (FOLD), Madrigal Pharmaceuticals (MDGL), Mylan (MYL), Spectrum Pharmaceuticals (SPPI), Akorn (AKRX), Fate Therapeutics (FATE), Karyopharm Therapeutics (KPTI) and Kura Oncology (KURA).

When did American Renal Associates IPO?

American Renal Associates (ARA) raised $161 million in an initial public offering on Thursday, April 21st 2016. The company issued 7,500,000 shares at a price of $20.00-$23.00 per share. BofA Merrill Lynch, Barclays and Goldman Sachs acted as the underwriters for the IPO and Wells Fargo Securities, SunTrust Robinson Humphrey and Leerink Partners were co-managers.

This page (NYSE:ARA) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners
The “Perfect Storm” for Gold
Gold Safe Exchange
Biden’s $374B Giveaway Into This Sector
DTI
Biden replacement revealed?
Paradigm Press
He Is Giving Away Bitcoin
Crypto Swap Profits
The #1 Crypto for 2024
InvestorPlace
Top 5 AI Stocks to Buy for 2024
Market Moving Trends
How Biden has already won 2024
Porter & Company
Options trading has suddenly become more reliable.
Eagle Publishing